eyeGENE(R)
Authors:
- 1 September 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 23 (5) , 355-363
Abstract
Purpose of review Molecular genetics is revolutionizing the diagnosis and treatment of inherited eye diseases. The National Eye Institute of the National Institutes of Health (NIH), in an effort to facilitate future basic and clinical research in inherited eye disease, created The National Ophthalmic Disease Genotyping and Phenotyping Network (eyeGENE). This review describes the process and utility of the eyeGENE program as it relates to ophthalmic clinical practice. Recent findings Over the last few years, genetic testing of specific genes associated with inherited eye conditions is becoming the standard practice. Vision research and human clinical trials relying on molecular genetic testing of individuals with inherited eye conditions are becoming more common. Eye healthcare professionals must consider the options to assist patients in obtaining genetic testing results and locating trials or studies that may have benefit. Summary eyeGENE is a DNA repository and patient registry for inherited eye diseases coupled to phenotypic descriptors and molecular genetic information. Through eyeGENE, healthcare professionals throughout the United States and Canada can obtain Clinical Laboratory Improvement Amendments-certified clinical molecular genetic results on their patients. Researchers may request access to a de-identified database of phenotype and genotype information about eyeGENE participants and DNA aliquots for their research studies. eyeGENE also offers participants the option of being included in a patient registry, whereby they may be re-contacted if an approved clinical study for which they might qualify is offered.Keywords
This publication has 15 references indexed in Scilit:
- Stem cell therapy for retinal diseaseCurrent Opinion in Ophthalmology, 2012
- Gene therapy prevents photoreceptor death and preserves retinal function in a Bardet-Biedl syndrome mouse modelProceedings of the National Academy of Sciences, 2011
- Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degenerationProceedings of the National Academy of Sciences, 2011
- Functional and Behavioral Restoration of Vision by Gene Therapy in the Guanylate Cyclase-1 (GC1) Knockout MousePLOS ONE, 2010
- Protective Effects of Human iPS-Derived Retinal Pigment Epithelium Cell Transplantation in the Retinal Dystrophic RatPLOS ONE, 2009
- Long-Term Safety and Function of RPE from Human Embryonic Stem Cells in Preclinical Models of Macular DegenerationStem Cells, 2009
- Transplantation of Human Embryonic Stem Cell-Derived Photoreceptors Restores Some Visual Function in Crx-Deficient MiceCell Stem Cell, 2009
- Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I TrialHuman Gene Therapy, 2008
- Success in sight: The eyes have it! Ocular gene therapy trials for LCA look promisingGene Therapy, 2008
- Comprehensive survey of mutations in RP2 and RPGR in patients affected with distinct retinal dystrophies: genotype–phenotype correlations and impact on genetic counselingHuman Mutation, 2006